OncoMatch/Clinical Trials/NCT06632860
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Is NCT06632860 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-TATE-RGD and 18-FDG for iodine-resistant thyroid cancer.
Treatment: 68Ga-TATE-RGD · 18-FDG — The US FDA approved a targeted somatostatin receptor 2 imaging agent, 68Ga-DOTATATE, in 2016. It has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer. Integrin αvβ3 is highly expressed in some tumor cells and new blood vessels, making it an ideal target for targeted diagnosis and treatment of tumors and tumor vessels.68Ga-labeled DOTA-TATE-RGD is a new type of tumor-specific imaging agent developed by researchers based on the above foundation, which is used for targeted diagnosis and internal radiation therapy for patients with SSTR2 and αvβ3 positive tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: SSTR positive by imaging
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Required: ITGB3 RGD-positive by imaging
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06632860 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require SSTR?
Yes, SSTR positive by imaging is a required biomarker for enrollment.
Does this trial require ITGB3?
Yes, ITGB3 RGD-positive by imaging is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify